🚀 Building a website? Start with reliable WordPress hosting from MilesWeb →
Business news, market intelligence, and global industry analysis.
The Latest

Natco Pharma faces legal setback for Imbruvica generic in US

bySrinath
August 21, 2021
Total
0
Shares
0
0
0

Natco Pharma Limited said that a US District Court has given a decision in favor of Pharmacyclics, a subsidiary of AbbVie, the brand owner of Imbruvica (ibrutinib) in a PIV litigation that involved the cancer drug.

The Indian pharma company said that it will review the judgment and assess all options for appealing the judgment, alongside Alvogen Pine Brook, its marketing partner in the US for the product.

Natco Pharma said that it has a strong case and will continue to vigorously defend it.

Natco Pharma faces legal setback for Imbruvica generic in US
Natco Pharma faces legal setback for Imbruvica generic in US. Image courtesy of 3D Animation Production Company from Pixabay.

In 2018, the Hyderabad-based firm and Alvogen Pine Brook had filed an abbreviated new drug application (ANDA) with PIV certification for the generic equivalent of Imbruvica.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Gan & Lee gets FDA orphan drug status for GLR2007 in malignant glioma
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

NKF to invest $95m in US generic injectables company Meitheal

Pharma acquisition news : Hong Kong King-Friend Industrial Company, a subsidiary of Chinese manufacturer Nanjing King-Friend Biochemical Pharmaceutical Company (NKF), has agreed to increase its stake in US generic injectables company Meitheal Pharmaceuticals for $95 million. Following the completion of the transaction, which is likely to be in Q4 2019, NKF will have a majority stake […]

The post NKF to invest $95m in US generic injectables company Meitheal appeared first on PharmaNewsDaily.com.

bypharmanewsdaily